Significance of different response evaluation criteria in predicting progression-free survival of lung cancer with certain imaging characteristics

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor

(2014) Chun Huang et al.   Thoracic Cancer

Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor

(2013) Monika Uhrig et al.   ACADEMIC RADIOLOGY

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

(2010) Ho Yun Lee et al.   LUNG CANCER

Evaluation of lymph nodes with RECIST 1.1

(2008) L.H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

(2008) Simon J. Crabb et al.   JOURNAL OF CLINICAL ONCOLOGY